同期肝肿瘤脾脏切除治疗原发性肝癌合并门脉高压症手术安全性与有效性分析  

Analyse the safety and effectiveness of simultaneous liver tumor andspleen resection on the treatment of primary liver cancer combined with portal hypertension

作　　者：蔡鸿宇[1] 张素青[1] 邵冰峰[1] 潘金锋[1] 张一心[1] 

机构地区：[1]江苏省南通市肿瘤医院肝胆外科,226361

出　　处：《齐齐哈尔医学院学报》2013年第18期2667-2669,共3页Journal of Qiqihar Medical University

摘　　要：目的探讨同期肝肿瘤脾脏联合切除治疗原发性肝癌合并门脉高压症手术的安全性与有效性。方法回顾性分析我院肝胆外科2007年7月至2013年4月12例原发性肝癌合并门脉高压症实施同期肝肿瘤脾脏切除术病例。结果全组无手术死亡病例。术后所有患者均出现不同程度的肝功能损害及腹水,经治疗后消退。脾机能亢进症状明显改善,术前AFP升高患者术后1月恢复正常。结论原发性肝癌合并门静脉高压症患者同期行肝癌切除联合脾切除术安全、有效。严格掌握手术指征及加强围手术期处理是提高近期疗效的关键。Objective To explore the safety and effectiveness of Simultaneous Spleen resection on the treatment of primary liver cancer combined with portal hypertension. Methods Retrospectively analyzethe datas of 12 patientswith primary liver cancer combined with portal hypertension who underwent simultaneous Liver Tumor and Spleen resection during July 2007 to April 2013 in department of liver and gallbladder surgery in our hospital. Results None operative death occurred in this study,but a certain extent of liver function damage and ascites occurred for all patients postoperatively, and subsided after treatment. Hypersplenism symptoms released significantly after surgery, and patients with preoperative elevated AFP were back to normal 1 month postoperate. Conclusions Simuhaneous liver tumor andspleen resection is safe and effective for patients with primary liver cancer combined with portal hypertension. Grasping the operation indication strictly and strengthen the preoperative management is the key step to improve the curative effect.

关 键 词：原发性肝癌 门静脉高压症 脾机能亢进 肝脾联合切除 

分 类 号：R657.31[医药卫生—外科学]